iShares MSCI Singapore ETF vs Nuwellis Inc — how do they compare? iShares MSCI Singapore ETF trades at $33.68, while Nuwellis Inc trades at $1.41 (market cap $542.80K). The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| EWS | NUWE | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $33.92 | $220.50 |
52-Week Low | $26.71 | $1.42 |
Market Cap | — | $542.80K |
Enterprise Value | — | -$1.27M |
Signals from Pluang's Aura AI — not financial advice
EWS, the iShares MSCI Singapore ETF, trades at $33.64, up 1.42% and hitting a new 52-week high. Technical indicators show a bullish moving average trend but overbought oscillators. The ETF benefits from Singapore's economic resilience, AI-driven growth, and a 3.97% dividend yield, with institutional interest rising as Amundi increased holdings by 4.8% in Q2 2026.
Outlook is positive due to strong momentum and structural growth in Singapore's financial and tech sectors. Risks include concentrated exposure to financials (54% of holdings) and sensitivity to Asian market volatility. The ETF offers diversification but requires monitoring for overextension near all-time highs.
NUWE trades at $1.41, down 0.7% today, with a bearish technical signal despite oversold RSI readings. The company reported a net loss of $17.52 million on $8.27 million revenue in 2025, with negative cash flow from operations. Recent news highlights expansion in pediatric care and a $3.4 million direct offering in July 2026, alongside a reverse stock split executed in June 2026.
Outlook remains challenged by persistent losses and high cash burn, though revenue growth and product development offer potential. Risks include reliance on financing and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid fundamental weaknesses.
Trailing returns across standard periods
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →